Windtree Therapeutics, Inc. (NASDAQ:WINT) Short Interest Update

Windtree Therapeutics, Inc. (NASDAQ:WINT) was the recipient of a significant increase in short interest during the month of March. As of March 31st, there was short interest totalling 279,300 shares, an increase of 466.5% from the March 15th total of 49,300 shares. Approximately 37.3% of the shares of the company are sold short. Based on an average trading volume of 2,720,000 shares, the short-interest ratio is presently 0.1 days.

Windtree Therapeutics Stock Performance

Shares of WINT stock traded up $0.03 during mid-day trading on Monday, hitting $1.36. 238,241 shares of the stock were exchanged, compared to its average volume of 725,667. The stock’s fifty day simple moving average is $3.09 and its two-hundred day simple moving average is $19.28. Windtree Therapeutics has a 12-month low of $1.10 and a 12-month high of $737.44. The stock has a market capitalization of $1.02 million, a price-to-earnings ratio of -0.08 and a beta of 0.91.

Hedge Funds Weigh In On Windtree Therapeutics

A hedge fund recently bought a new stake in Windtree Therapeutics stock. Renaissance Technologies LLC bought a new position in shares of Windtree Therapeutics, Inc. (NASDAQ:WINT) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 119,266 shares of the company’s stock, valued at approximately $42,000. Renaissance Technologies LLC owned 1.08% of Windtree Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). 29.33% of the stock is currently owned by hedge funds and other institutional investors.

About Windtree Therapeutics

Windtree Therapeutics, Inc, a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company’s lead product candidate is istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock.